Federal Legislation
Congress Advances ISLET Act to Reclassify Pancreatic Islets
March 19, 2026
Congressional lawmakers, led by Representative Ralph Norman, have introduced the ISLET Act to reclassify pancreatic islets from drugs to organs. This legislative change aims to remove federal regulatory barriers that currently restrict access to islet transplants for Americans with type 1 diabetes. By redefining pancreatic islets as organs, the Act is expected to expand patient access to this critical treatment and stimulate innovation in diabetes care and transplantation technologies.
- Why this matters: Federal procurement and regulatory frameworks related to organ transplantation and medical treatments may be impacted, potentially altering compliance requirements for contractors and suppliers in the healthcare sector.
- Procurement professionals should anticipate changes in FDA oversight and related contracting opportunities as the ISLET Act progresses through Congress and potentially becomes law.
- Medical device and biotech companies involved in islet transplantation technologies may find new market opportunities as regulatory pathways shift.
- Agencies involved in healthcare procurement and transplantation services should evaluate how this reclassification could affect existing contracts and future solicitations.
The ISLET Act will help expand access to life-saving care and support continued innovation in diabetes treatment.
— Rep. Ralph Norman
Agencies
House of Representatives, Senate, Secretary of Health and Human Services
Locations
Sources
- Introducing the ISLET Act | U.S. Representative Ralph Norman · Norman House · Mar 19